A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.
about
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenovirusesVirotherapy: cancer gene therapy at last?Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpointsA dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibitionA novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous routeA pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.Virotherapy against malignant glioma stem cellsThe in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunityAdenoviral vector-mediated gene therapy for gliomas: coming of age.Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cellsRole of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)Cancer stem cells: the final frontier for glioma virotherapy.Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activityThe HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma CellsGene therapy for malignant glioma.Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.Gene therapy trials for the treatment of high-grade gliomas.Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific AntigensVascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapyIntravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases.Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer modelOncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activityAdenoviral virotherapy for malignant brain tumorsArming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.Strategies in gene therapy for glioblastoma.Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes.Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization.A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replicationA Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells.Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death.
P2860
Q21144267-A33724C7-FC76-4D27-A964-2A76C7B17144Q28066228-8925F898-10E4-4D3A-8A40-11320112E86BQ28083515-B82D1506-D937-4D72-B164-8627BD398D54Q28477181-940A91A4-39B8-40C2-927D-326819C39CDDQ28817910-D6301D4E-F068-4C74-938D-7495F38C44ABQ33586974-A8BE5B5E-5478-4224-946C-CCF6A1D0CD36Q33633272-BD5A32C6-BC03-4E76-9A23-F588CEE77711Q33665530-DF8A08B4-AE1A-42C8-81C4-80E9718579AAQ33670728-5C6C411C-F35F-4BDF-9D36-5E7295F58705Q34022048-789E16C0-354B-4F62-92C7-FE795CCFD703Q34102273-07F843FD-5778-49E4-A890-A5710C36C5C9Q34154904-0425A7AA-C35B-4A2D-ACD5-F71BA6303800Q34433546-8B80560E-9857-4431-B208-71F8BF78C0D2Q34516701-FB6FD8CE-C0ED-40C3-939F-07F7970A5D03Q35076737-73822EB9-1824-447C-A326-0C1EDC6DB100Q35636540-5A8DCC0E-1FC8-4D87-8357-486F7A4FDA7DQ35673628-8CE71529-7924-4282-A45C-595F6D68BD80Q35754085-70A8B6D6-E616-419B-8B8C-C8E837EBF4DEQ35874291-7F1E26F5-C42B-4325-8F88-4B833DC0963CQ35880459-72BB089E-F70C-46D8-A850-4116D3CF9731Q35993889-DE3A14A8-CBB0-4F25-89D0-6B226068B10CQ36387929-514FB207-A14A-4FDA-8D6F-08B7608A2EBAQ36387946-B79D9228-756F-480A-BD50-607586CE34BFQ36478219-3FB0F259-02DB-4E2F-ABB9-25A388B73222Q36634430-8C400DF5-6950-49E4-9DFC-02E2C694C61DQ37127836-9029BB3C-1150-41B7-8248-973D717C2953Q37223357-278ABF83-D4B1-43E6-9652-84225D297B3EQ37223846-3DE0B233-FA0D-441B-81CB-C9C8B2CB22B3Q37346958-B6CF1C0B-1E57-4E5E-ABCD-123ABF13DC9BQ37420576-0956D9A4-E9AD-4315-A933-2888D26E7080Q37804933-DFDA51C3-B1B7-487E-84BB-4FEE68DA4165Q38718750-86B57FB6-B104-4DBF-B830-FCFD8F997DF7Q38752688-E4197965-5EA4-4378-B615-5B568996A17BQ38968578-C3DD8E9F-99D5-4641-A063-B7799AAE380CQ39606511-6B7DD87A-3373-464D-9BCA-FE87B13B1477Q39682554-ED3BC3EC-98C2-49A4-B227-B4EB7AA98E6AQ39685348-75D1ABBE-DC28-49B8-81A4-0DC35BEBAAD2Q39701557-91BB7122-AFE5-498C-A206-3D90C8293979Q40273594-EAA1049F-4107-4C7A-ABAF-7142005234EBQ40277603-7F6108E6-D434-44E4-9441-A270868309B2
P2860
A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A conditionally replicative ad ...... ws improved oncolytic potency.
@ast
A conditionally replicative ad ...... ws improved oncolytic potency.
@en
type
label
A conditionally replicative ad ...... ws improved oncolytic potency.
@ast
A conditionally replicative ad ...... ws improved oncolytic potency.
@en
prefLabel
A conditionally replicative ad ...... ws improved oncolytic potency.
@ast
A conditionally replicative ad ...... ws improved oncolytic potency.
@en
P2093
P1476
A conditionally replicative ad ...... ows improved oncolytic potency
@en
P2093
P304
P407
P577
2001-01-01T00:00:00Z